Karyopharm Therapeutics Inc (KPTI) CEO Sells $100,900.00 in Stock

Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $10.09, for a total value of $100,900.00. Following the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at approximately $5,268,422.87. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Michael Kauffman also recently made the following trade(s):

  • On Monday, December 18th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $9.16, for a total value of $91,600.00.

Karyopharm Therapeutics Inc (NASDAQ KPTI) traded up $0.26 on Monday, reaching $10.27. The company had a trading volume of 238,042 shares, compared to its average volume of 194,779. Karyopharm Therapeutics Inc has a 12-month low of $7.48 and a 12-month high of $14.63. The firm has a market cap of $484.55, a price-to-earnings ratio of -3.86 and a beta of 4.08.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. sell-side analysts predict that Karyopharm Therapeutics Inc will post -2.58 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. lifted its holdings in Karyopharm Therapeutics by 7.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 150,289 shares of the company’s stock worth $1,443,000 after purchasing an additional 9,929 shares during the last quarter. Iguana Healthcare Management LLC lifted its holdings in Karyopharm Therapeutics by 33.3% in the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after purchasing an additional 100,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Karyopharm Therapeutics by 753.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after purchasing an additional 271,208 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in Karyopharm Therapeutics by 16.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock worth $5,600,000 after purchasing an additional 72,000 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in Karyopharm Therapeutics by 396.0% in the 3rd quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock worth $1,160,000 after purchasing an additional 84,362 shares during the last quarter. Hedge funds and other institutional investors own 60.89% of the company’s stock.

Several equities research analysts have recently issued reports on KPTI shares. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. BidaskClub lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. started coverage on Karyopharm Therapeutics in a report on Wednesday, November 15th. They set a “buy” rating and a $23.00 price target for the company. Royal Bank of Canada reiterated a “buy” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.33.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics Inc (KPTI) CEO Sells $100,900.00 in Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/22/karyopharm-therapeutics-inc-kpti-ceo-sells-100900-00-in-stock.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply